Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)    
Revenues
Operating expenses:    
General and administrative 69,014 79,843
Total operating expenses 69,014 79,843
Loss from operations (69,014) (79,843)
Other expense:    
Loss on fair value adjustment - derivatives (800)
Interest expense (63,886) (64,027)
Amortization - beneficial conversion feature (5,356)
Total other income (expense) (70,042) (64,027)
Net loss (139,056) (143,870)
Net loss attributable to noncontrolling interest 767 821
Net loss attributable to TranBiotec, Inc. $ (138,289) $ (143,049)
Net loss per share    
(Basic and fully diluted) $ (0.001) $ (0.001)
Weighted average number of common shares outstanding 130,145,018 109,409,930